![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 300, Issue 3, 976-983, March 2002
Department of Pathology and Laboratory Medicine (W.M.L., M.B.B.)
and Faculty of Pharmaceutical Sciences (L.D.M.), University of British
Columbia, Vancouver, British Columbia, Canada; and Department of
Advanced Therapeutics, British Columbia Cancer Agency, Vancouver,
British Columbia, Canada (W.M.L., M.B.B., L.D.M.)
One of the major obstacles in the development of ligand-targeted
liposomes is poor liposome circulation longevity as a result of
antibody-mediated elimination of these highly immunogenic carriers. Because studies from our laboratory suggest that it is not possible to
reduce the immunogenicity of ligand-conjugated liposomes by using
surface-grafted poly(ethylene glycol) (PEG), we investigated the
usefulness of PEG in protecting hapten-conjugated liposomes from
elimination by an existing immune response that was previously established against the hapten. Using biotin as a model hapten, a
strong biotin-specific antibody response was generated in mice by using
bovine serum albumin-biotin. When these animals were challenged
with liposomes containing biotin-conjugated lipid (1 or 0.1%), these
liposomes were rapidly eliminated. Incorporation of PEG-lipids into
these liposomes substantially reduced biotin-specific antibody binding
as measured using an in vitro antibody consumption assay. However,
depending on the hapten concentration, significant reductions in
antibody binding through the use of PEG-lipids may not be sufficient to
protect these liposomes from rapid elimination in vivo. Complete
protection of liposomes was only achieved when the biotin concentration
on liposome surface was low (0.1%) and with 5 mol% of either
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] or
1,2-dipalmatoyl-sn-glycero-3-phosphoethanolamine-n-methoxy(polyethylene glycol)-2000]. The use of
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] (up to 15 mol%) was not effective in protecting liposomes from rapid elimination in vivo, indicating the limited usefulness of this highly exchangeable PEG-lipid. In conclusion, our in
vivo and in vitro data indicate that liposomes can be protected from
antibody-mediated elimination by using the right type and concentration
of PEG-lipids. This result has important implication in the development
of ligand-targeted liposomes.